HIV Treatment
Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Sunday, 16 April 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.
Full coverage listing by topic
4/16/17
Obituary: Pioneering HIV Researcher Mark Wainberg
- Details
- Category: HIV Treatment
- Published on Friday, 14 April 2017 00:00
- Written by Liz Highleyman
Mark Wainberg, a highly regarded clinician and researcher who helped advance HIV therapy and advocated for access to treatment and care worldwide, died on April 11 in a swimming accident in Florida at age 71.
CROI 2017: Dolutegravir Monotherapy Fails to Maintain Viral Suppression
- Details
- Category: HIV Treatment
- Published on Wednesday, 08 March 2017 00:00
- Written by Liz Highleyman
Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard 3-drug combination regimen, according to research presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. But evidence continues to show that dolutegravir plus a single other drug can work well as maintenance therapy.
CROI 2017: How Does Vedolizumab Antibody Therapy Lead to Sustained Viral Remission?
- Details
- Category: Search for a Cure
- Published on Thursday, 16 March 2017 00:00
- Written by Liz Highleyman
HIV and its monkey cousin SIV can carry the alpha-4 beta-7 integrin receptor in their outer envelope, which helps the virus enter gut cells during early infection, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. This finding may help explain how an antibody against alpha-4 beta-7 produced sustained viral remission in monkeys.
CROI 2017: Integrase Inhibitors May Increase Risk of IRIS in Late Presenters for HIV Treatment
- Details
- Category: HIV Treatment
- Published on Wednesday, 08 March 2017 00:00
- Written by Keith Alcorn
HIV integrase inhibitors such as dolutegravir and raltegravir may increase the risk of immune reconstitution inflammatory syndrome or IRIS, according to studies from the Netherlands and France presented last month at the Conference on Retroviruses and Opportunistic Infections in Seattle.
More Articles...
- CROI 2017: Several New Candidates in HIV Drug Pipeline Discussed at Conference
- CROI 2017: Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV
- CROI 2017: Bone Marrow Transplant Patient Off ART for 288 Days Without HIV Rebound
- CROI 2017: Time with Transmissible HIV Viral Load Has Fallen By Three-Quarters Since 2000
Web Design and Development by